What type of study is this?

September 10, 2025JAC-Antimicrobial ResistanceOpen Access

In vivo pharmacokinetics, therapeutic efficacy and immune response of bacteriophage vB_AbaSt_W16 against carbapenem-resistant Acinetobacter baumannii

View Full Paper

Ask AI

Bookmark

Bacteriophage vB_AbaSt_W16 significantly reduced carbapenem-resistant bacteria by 4–7 log₁₀ cfu/mL within 24 hours, demonstrating its antibacterial efficacy.
Phage vB_AbaSt_W16 achieved peak concentrations at 8 hours post-administration, indicating rapid systemic distribution in murine models.
Intraperitoneal administration resulted in higher systemic bioavailability compared to oral administration, enhancing bacterial clearance.
Phage treatment did not induce major pro-inflammatory responses, highlighting its potential safety profile in therapeutic applications.

No takes yet. Share an insight, caveat, or question.

In vivo analysis shows bacteriophage treatment reduces bacterial loads in murine infections, suggesting potential for alternative therapy.

Choi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

In vivo analysis shows bacteriophage treatment reduces bacterial loads in murine infections, suggesting potential for alternative therapy.